-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Gardiquimod-diTFA
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1159840-61-5.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 1159840-61-5 |
| Description | Gardiquimod diTFA, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod diTFA could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 when used at concentrations below 10 μM. |
Product Information
| Synonyms | Gardiquimod (diTFA)|HY-103697A |
| Molecular Weight | 541.44 |
| Molecular Formula | C21H25F6N5O5 |
| Purity | 99.77% |
| Solubility | In Vitro: DMSO : 50 mg/mL(92.35 mM;Need ultrasonic) H2O : 25 mg/mL(46.17 mM;Need ultrasonic) In Vivo: 1.Add each solvent one by one:PBS Solubility: 50 mg/mL (92.35 mM); Clear solution; Need ultrasonic 2.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.62 mM); Clear solution 3.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (4.62 mM); Clear solution 4.Add each solvent one by one:10% DMSO >> 90%corn oil Solubility: ≥ 2.5 mg/mL (4.62 mM); Clear solution |
| Appearance | White to off-white (Solid) |
| Storage | 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months -20°C, 1 month (sealed storage, away from moisture) |
| Target | Toll-like Receptor (TLR); HIV |
